
jun pm et
summari compani develop manufactur market proprietari specialti health care
product eye care women health
price-to-earnings oper ep
custom tend brand loyal come
contact lens howev off-set increas
competit contact lens new technolog
laser surgeri
aug ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
jun pm stock trade
estim oct revenu rise
billion follow
increas estim assum
organ sale growth
remain gain come paragon
vision paragard acquisit see
continu organ top-lin growth
coopervis driven increas toric
multifoc well price growth
increas adopt daili lens view
paragard acquisit posit
paragard approv non-hormon
mid-singl digit although
growth potenti product given
low market penetr potenti
expect coo gross margin expand
reflect improv sale
streamlin benefit synergi recent
acquisit partial off-set unfavor
impact foreign currenc exchang
project oper ep
oper
ep
recommend buy
success grown key franchis
strateg expans invest
high-tech lens foreign market
take market share larg
competitor win new wearer
trade exist user daili lens
market share gain mostli retain
consum unlik switch
brand initi select made
expect user transit
daili contact given conveni
forecast price growth mix
shift also view potenti growth
coopervis favor see paragard
depend revenu stream coopersurg
go forward consid
risk recommend target price
product launch slowdown demand
daili contact lens
weaker-than-expect growth emerg
target price reflect
price-to-earnings multipl ep estim
slightli peer averag
expect continu increas sale
faster rate overal market
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview compani develop manufactur market health care product
two busi unit coopervis coopersurg csi account net
sale fy oct csi repres balanc
coopervis develop manufactur market broad rang contact lens world-wide vision
care market contact len market two major product categori spheric lens includ
lens correct near- farsighted uncompl complex visual defect toric
multifoc lens includ lens addit correct near- farsighted address
complex visual defect astigmat presbyopia sale fy product categori
broke follow single-us sphere non-singl use sphere toric len
multi-foc len sale fy geograph market america emea
coopersurg offer broad array product servic focus advanc health famili
portfolio product servic focus women health includ medic devic
fertil genom diagnost contracept csi offer product technolog servic
clinician patient world-wide csi collabor clinician identifi product new
technolog dispos product diagnost test sophist instrument equip
bring new product market csi also compet global invitro fertil ivf market
product portfolio ivf media assist reproduct technolog solut design enhanc
work fertil profession benefit famili
major develop januari acquir ocular scienc osi fifth largest contact
len manufactur billion cash stock acquisit osi made third
largest manufactur term market share provid access new technolog
particularli patent silicon hydrogel single-us len technolog new geograph market
particularli japan germani higher volum manufactur process juli acquir
origio maker in-vitro fertil product million august compani acquir
ltd european manufactur distributor soft contact lens
solut billion acquisit provid daili contact lens offer
clariti brand single-us sphere toric multi-foc silicon hydrogel lens august
acquir reprogenet llc genet laboratori special servic offer preimplant
genet screen preimplant genet diagnosi use ivf process million
may complet acquisit recombin inc base clinic genet test compani
special carrier screen million novemb wallac ivf segment
smith medic intern million novemb acquir paragard product line
billion paragard non-hormon copper intrauterin devic
approv birth control
market profil total world-wide sale soft contact lens increas calendar latest
avail approxim billion accord compani categori global sale sphere
market toric lens multifoc single-us lens
account total market modal repres geograph market
america account total sale emea asia/pacif
base compani data account almost global soft contact len market
johnson johnson vistakon divis alcon divis novarti ag
bausch lomb compani account remain told world-wide
contact len market like continu grow mid-singl digit annual next five year
advanc len technolog silicon hydrogel materi drive adopt contact
lens view howev compet technolog includ laser vision surgeri becom cheaper
preval len manufactur face addit competit threat
financi trend fy net sale increas billion billion fy
octob total cash short term invest balanc million
billion long-term debt
presid
senior vice-president financ
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc june technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
neutral fundament outlook
health care suppli sub-industri next
month although think mani suppli
categori histor larg
recession-resist concern
demand trend area typic view
non-elect basic hospit suppli
steril equip bed stretcher
blood collect product tie
hospit spend budget saw pickup
albeit uneven spend
product suggest us mani
hospit begun replac age suppli
equip
health care reform law neutral
effect health care suppli
sub-industri view benefit
greater number insur patient
off-set price pressur fee
implement medic devic tax
seek rais total billion
year took effect consolid
appropri act sign decemb
suspend medic devic
excis tax two year begin
januari trump
administr sign new law extend
moratorium addit two year levi
incom tax deduct lower
after-tax effect mani compani
expect benefit coverag
million previous uninsur individu
certain person item contact lens
hear aid subject tax
moreov mani compani deriv increas
portion revenu non-u market
also subject tax
expect republican administr
continu effort repeal
could rise hospit facil
would lead lower profit lower
demand health care suppli senat
fail multipl time gather
suffici number vote pass variou
repeal replac bill republican
success elimin individu
mandat passag tax cut
job act decemb see
develop neg health care
suppli provid given fewer custom
choos enrol insur plan
see demand suppli continu
driven replac cycl time
improv same-stor patient admiss
increasingli fuel age babi
boomer gener meanwhil still see
howev continu see price pressur
reimburs risk
year date march
increas composit
 health suppli
rose vs increas
base index
five-year market price perform jun
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
report apr-q oper ep vs
consensu apr-q sale increas growth vision aid
increas asia pacif region growth surgic expect
sale growth fy continu expand faster overal market
per compani inc rais target
fy oct ep estim multipl slight
premium peer reflect sale growth outlook expect modest
margin expans product mix shift increas fy fy ep
estim jan-q oper ep
vs capit iq consensu sale increas
growth vision growth surgic acquisit driven
growth fertil see sale growth fy aid market share
analyst research note compani news
et cfra maintain buy opinion share cooper
compani inc maintain target
in-lin peer ep estim
multipl near averag coo five-year rang
april-q ep vs higher estim
rais oct ep april-q sale increas
million coopervis revenu million
coopersurg revenu million expect pro-forma
revenu growth strong diversifi growth asia
pacif region continu momentum daili silicon hydrogel lens
coopersurg segment revenu growth driven coo late
acquisit paragard see potenti make strateg
acquisit near futur opportun present
expect pay debt /kevin huang cfa
compani inc rais target
fy oct ep estim line peer reflect
sale growth margin expans expect increas fy fy
ep estim report jan-q
oper ep vs consensu forma sale
increas growth vision partial off-set declin
surgic impact declin genet test see pro forma
sale growth fy driven vision market share gain recoveri
inc keep target fy
oct ep estim roughli line peer continu see improv
sale growth modest margin expans rais fy ep estim
adjust acquisit paragard expect fy
ep report oct-q oper ep vs line
consensu fy pro forma sale increas driven growth
coopervis growth coopersurg expect organ sale growth
fy aid strong growth asia pacif region /danni yang cfa
inc announc sign agreement purchas
global right paragard intrauterin devic teva pharmaceut
billion paragard current sold revenu
approxim million trail twelve-month period deal
subject customari close condit expect close end
financ transact bridg loan eventu
long term debt view deal posit given
accret operating/gross margin ep within first year /k
compani inc keep target
fy oct ep estim roughli line peer reflect
improv sale growth outlook expect modest margin expans
driven product mix shift rais fy fy ep estim
report jul-q oper ep
vs consensu jul-q sale increas driven
growth coopervis increas toric categori expect
sale growth fy aid strength emea asia pacif
compani inc rais target
fy oct ep estim slight premium peer
reflect improv sale growth margin expans expect
increas fy fy ep estim
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
